| Paris | |
| 0 | |
| Fundamental research in the detection and inhibition of proteases involved in human diseases | |
| Pharmaleads has two molecules in clinical development sharing the same mechanism of action, dual inhibition of enkephalinases, which makes them promising candidates to tackle the largely underserved field of severe pain. These compounds, PL37 and PL265, belong to two different chemical families, both fully patented, and their different chemico-physical properties allow a different positioning on the multi-billion markets of severe pain, whatever its location and its origin. -PL37, currently in Phase 2 by oral route, addresses all types of peripheral neuropathic pain. The first clinical of this first-in class compound, focusing on diabetic polyneuropathy is underway in 22 investigative sites across the UK, France and Bulgaria. Another indication for PL37 is the huge market of opiates, which are highly effective but poorly tolerated drugs; it will be administered intravenously to patients with severe pain caused by advanced cancer, surgery, traumatology. -PL265 is currently in Phase 1 by oral route and will be tested in 2016 as intrathecal treatment of breakthrough cancer pain in terminally ill patients.Thanks to its chemical structure, PL265 is also being developed as a topical treatment of all types of severe local pain. The next milestone for Pharmaleads pipeline is of course the outcomes of the Phase 2a study in diabetic polyneuropathy, expected Q2 2016. |
|
| BOURBIE Thierry | |
| www.pharmaleads.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 43 fois.